Skip to content

The efficacy and safety of percutaneous transluminal angioplasty (PTA) in the treatment of lower extremity arteriosclerosis obliterans (ASO):Open-label, prospective, multicenter, non-randomized controlled study

The efficacy and safety of percutaneous transluminal angioplasty (PTA) in the treatment of lower extremity arteriosclerosis obliterans (ASO):Open-label, prospective, multicenter, non-randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082678
Enrollment
Unknown
Registered
2024-04-03
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower extremity arteriosclerosis obliterans

Interventions

Experimental group:Constrained peripheral balloon dilation catheter treatment
Control group:Peripheral balloon dilation catheter treatment

Sponsors

First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) ASO patients diagnosed by CCD or CTA; 2) Age 18-80 years old; 3) Meet the indications for endovascular treatment; 4) lower extremity vascular disease; 5) Intermittent claudication or ischemic resting pain (Rutherford scale 2-4); 6) Significant (=70%) superficial femoral artery or popliteal artery stenosis (the length of the lesion stenosis is 20~180mm), manifested as intravascular revascularization; 7) At least one blood vessel in the distal outflow tract has unobstructed blood flow; 8) Complete case data.

Exclusion criteria

Exclusion criteria: 1) Grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval =470 ms); According to NYHA criteria, patients with grade ? to ? cardiac insufficiency or left ventricular ejection fraction (LVEF) 1.5 or prothrombin time (PT) > ULN+4 seconds or APTT >1.5 ULN), have a tendency to bleed or are receiving thrombolytic or anticoagulant therapy; 3) Leukocyte 2.5mg/dL; AST and/or ALT > 2 times the normal upper limit); 5) Congenital lower limb dysfunction or vascular disease; 6) Life expectancy < 12 months; 7) The investigator judges that it is not suitable to participate in the clinical trial; 8) Angiographic exclusion criteria include: A previous bypass graft or stent at the target vessel; The therapeutic balloon cannot pass through the iliac stent.

Design outcomes

Primary

MeasureTime frame
The incidence of intraoperative flow-restricted dissection;

Secondary

MeasureTime frame
Remedial stent implantation rate;Ankle-brachial index;The rate of freedom from target lesion revascularization;

Countries

China

Contacts

Public ContactYan Song

First Affiliated Hospital of Zhengzhou University

13838003397@139.com+86 138 3800 3397

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026